PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 18, 2026Frontiers in Cardiovascular Medicine0 citationsOpen Access

Complete revascularization and heart failure risk in acute coronary syndrome across the ejection fraction spectrum: focus on LVEF-dependent effects

XLXiaozhi LuoJNJiaan NongSXShaowei Xu

Key Result

Complete revascularization was associated with a significantly reduced risk of heart failure hospitalization or cardiovascular death in patients with acute coronary syndrome and an LVEF of 40%-50% (HR 0.46), though the adjusted benefit was not significant in the overall cohort with LVEF ≥ 40%.

Study Design

Type

Cohort (n=1,834)

Structured PICO

Does complete revascularization reduce the composite outcome of first hospitalization for heart failure or cardiovascular death in patients with acute coronary syndrome, multivessel disease, and LVEF ≥ 40%?

P
Population
1,834 patients with acute coronary syndrome (ACS), multivessel disease, and a left ventricular ejection fraction (LVEF) ≥ 40%
I
Intervention
Complete revascularization (CR), defined as percutaneous coronary intervention (PCI) of all suitable non-culprit lesions during index hospitalization or within 45 days postdischarge, alongside dual antiplatelet therapy and guideline-directed medical therapy
C
Comparator
Incomplete revascularization (ICR), alongside dual antiplatelet therapy and guideline-directed medical therapy
O
Outcome
Composite outcome of first hospitalization for heart failure (HF) or cardiovascular deathcomposite

Complete revascularization reduces the risk of heart failure hospitalization or cardiovascular death in ACS patients with multivessel disease and mildly reduced ejection fraction (40-50%), particularly in those with NSTE-ACS.

Main Result

Effect estimate: HR 0.56 (95% CI 0.38-0.83)

Absolute Event Rate: 4.6% vs 7.8%

p-value: p=<0.001

Limitations

  • Retrospective, observational design with potential for residual confounding and selection bias
  • Data on the proportion of non-culprit lesions treated based on physiology versus angiography were not systematically recorded
  • Residual SYNTAX score or comparable metric of anatomic completeness was not recorded
  • Limited number of cardiovascular mortality events introduces uncertainty into absolute risk reduction estimates
  • Lack of long-term follow-up data and absence of a time-updated medication model
  • Missing exact dates for CABG surgery in most cases
  • observational nature of this study
  • potential for residual confounding

Abstract

Objective To investigate the impact of complete revascularization (CR) versus incomplete revascularization (ICR) on the composite outcome of first hospitalization for heart failure (HF) or cardiovascular death in patients with acute coronary syndrome (ACS) and a left ventricular ejection fraction (LVEF) ≥ 40%. Methods This retrospective study enrolled 1,834 patients with ACS, multivessel disease, and an LVEF ≥ 40% (767 CR and 1,067 ICR). CR was defined as percutaneous coronary intervention (PCI) of all suitable non-culprit lesions during index hospitalization or within 45 days postdischarge. The primary endpoint was the first occurrence of hospitalization for HF or cardiovascular death. At discharge, almost all patients received dual antiplatelet therapy and guideline-directed medical therapy. Result During the follow-up period, 35 of the 767 patients (4.6%) in the CR group and 83 of the 1,067 (7.8%) patients in the ICR group reached the primary endpoint ( p 0.001). After adjusting for covariates, CR was associated with a lower risk of the primary endpoint in the population with an LVEF 50% hazard ratio (HR), 0.46; 95% confidence interval (CI), 0.22–0.96. This benefit was confined to patients with non-ST-segment elevation ACS (NSTE–ACS) (HR 0.41; 95% CI 0.20–0.83) but was not observed in the ST-segment elevation myocardial infarction (STEMI) subgroup. Conclusion CR is associated with a significantly reduced risk of HF hospitalization or cardiovascular death in patients with an LVEF of 40%–50%. This benefit attenuated as the LVEF increased, highlighting a potential LVEF-dependent efficacy. Although these results are promising, the observational nature of this study and the potential for residual confounding necessitate cautious interpretation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Luo et al. (2026) conducted a cohort in Acute coronary syndrome with multivessel disease and LVEF ≥ 40% (n=1,834). Complete revascularization vs. Incomplete revascularization (culprit-only) was evaluated on First occurrence of hospitalization for heart failure or cardiovascular death (HR 0.56, 95% CI 0.38-0.83, p=<0.001). Complete revascularization was associated with a significantly reduced risk of heart failure hospitalization or cardiovascular death in patients with acute coronary syndrome and an LVEF of 40%-50% (HR 0.46), though the adjusted benefit was not significant in the overall cohort with LVEF ≥ 40%.

synapsesocial.com/papers/6a0fc700d13714ec96fe97a2https://doi.org/10.3389/fcvm.2026.1830626
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Complete Revascularization in NSTE-ACS and Multivessel Disease: Clinical Outcomes and Prognostic Implications2025
  2. 2Impact of Complete Revascularization on Development of Heart Failure in Patients With Acute Coronary Syndrome and Multivessel Disease: A Subanalysis of the CORALYS Registry2023 · 14 citations
  3. 3Complete Revascularization of Multivessel Coronary Artery Disease Does Not Improve Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction2020 · 8 citations
  4. 4The Reduction of Left Ventricle Ejection Fraction after Multi-Vessel PCI during Acute Myocardial Infarction as a Predictor of Major Adverse Cardiac Events in Long-Term Follow-Up2022 · 5 citations
  5. 5Effect of Complete Revascularization in STEMI: Ischemia-Driven Rehospitalization and Cardiovascular Mortality2025